Lv5
1140 积分 2024-04-09 加入
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
2个月前
已关闭
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
2个月前
已完结
脐尿管癌的临床特征及预后相关因素分析
3个月前
已完结
脐尿管癌生存的预测模型和改良分期系统的构建:基于SEER数据库的真实世界研究
3个月前
已完结
Clinicopathologic Features and Response to Therapy ofNRG1Fusion–Driven Lung Cancers: The eNRGy1 Global Multicenter Registry
4个月前
已完结
First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC)
4个月前
已关闭
Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors
4个月前
已完结
晚期腹膜后去分化脂肪肉瘤1例并文献复习
8个月前
已完结
皖公网安备34019202002308
